Overview of Tussionex

This foundational section provides a clear definition and classification of the medication Tussionex, focusing on its composition, form, and general therapeutic identity.

Property	Description
Active Ingredients	Hydrocodone Bitartrate, Phenyltoloxamine
Form	Extended-release oral suspension (liquid)
Pharmacological Class	Narcotic Antitussive and First-Generation Antihistamine
Common Use	Symptomatic relief of cough and associated upper respiratory symptoms
Origin	Semi-synthetic/Synthetic compound

Defining Tussionex: Class and Combination

Tussionex is classified as a fixed-dose combination product containing two active pharmaceutical ingredients, a narcotic antitussive and an antihistamine, used for the symptomatic relief of upper respiratory conditions. The primary component, Hydrocodone Bitartrate, is a semi-synthetic opioid agonist that acts centrally to suppress the cough reflex, a mechanism for suppressing the cough reflex. The second ingredient, Phenyltoloxamine, is a synthetic first-generation antihistamine that contributes to relief by addressing associated symptoms, such as those related to histamine release. This prescription-only pairing is a key differentiator from many over-the-counter products, designed for powerful, dual-action effect in managing conditions that involve persistent cough.

Composition and Extended-Release Formulation

The identity of this medication is the extended-release oral suspension, a liquid preparation for oral administration. The two active agents, Hydrocodone and Phenyltoloxamine, are formulated utilizing proprietary polistirex resin technology. This unique system involves binding the active ingredients to tiny ion-exchange polymer particles to achieve a sustained release profile. The formulation is designed to prolong the duration of the drug's therapeutic action, allowing for a simplified, less frequent administration schedule to maintain consistent relief, particularly useful in managing nighttime cough episodes.

General Purpose and Mechanism of Action

The general therapeutic purpose of Tussionex is to provide powerful and sustained symptomatic relief of cough and certain concurrent upper respiratory symptoms. This is achieved through the dual mechanism of action: Hydrocodone acts directly on the brain's cough center to elevate the cough threshold, while the antihistamine, Phenyltoloxamine, works as an H1 receptor antagonist. This combined action ensures comprehensive and sustained symptom management, a benefit typically sought in cases where a persistent cough significantly disrupts daily activities or sleep.

Regulatory References

NIH/NLM Drug Record

What side effects are possible with Tussionex?

Possible Side Effects and Safety Information

Adverse reactions associated with Tussionex (Hydrocodone Bitartrate and Phenyltoloxamine Polistirex) are categorized based on official government regulatory documents. The most frequently reported effects relate to the central nervous system (CNS) and the gastrointestinal tract, reflecting the actions of the narcotic antitussive and the first-generation antihistamine components.

Official Adverse Reaction Scope

System-Organ Class (SOC)	Most Frequently Reported Adverse Reactions
Nervous System Disorders	Drowsiness, Sedation, Dizziness, Impaired mental and physical performance.
Gastrointestinal Disorders	Constipation, Nausea, Vomiting, Dry mouth.
General & Psychiatric	Fatigue, Anxiety, Pruritus (itching).

Serious Adverse Reactions and Safety Constraints

The regulatory safety profile highlights several serious adverse reactions, primarily associated with the opioid constituent. The most serious risk is Respiratory Depression, which is potentially life-threatening. The official labeling also documents the potential for developing Drug Dependence and Abuse with long-term use, alongside the risk of Serotonin Syndrome when used concurrently with certain other medications.

Safety notes specify that effects like drowsiness and sedation may impair the ability to perform hazardous tasks. Furthermore, the combination of this product with other CNS depressants significantly potentiates the risks of profound sedation and respiratory depression.

Population-Specific Safety Considerations

Official documents indicate that older adults are more susceptible to the adverse effects, including a heightened risk of respiratory depression and sedation. Caution is also documented for use in patients with pre-existing hepatic or renal impairment due to the possibility of altered drug clearance, which may increase the risk of adverse reactions.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of the hydrocodone/phenyltoloxamine combination is a serious, life-threatening emergency primarily defined by profound central nervous system (CNS) and respiratory depression. Officially documented manifestations of overdose include profound somnolence, potentially advancing to stupor or coma, and clinical signs such as skeletal muscle flaccidity and characteristic pinpoint pupils (miosis). Severe physiological outcomes involve the cardiovascular system, presenting as hypotension and bradycardia, which can escalate rapidly to circulatory collapse, cardiac arrest, and death.

Due to the severity of these documented risks, regulatory authorities mandate that immediate medical attention must be sought for any suspected overdose. Contacting emergency services is required for signs of severe respiratory depression or unresponsiveness. The management protocol focuses on maintaining an adequate airway, initiating assisted ventilation, and administering the specific opioid antagonist Naloxone to reverse life-threatening respiratory effects. Because Tussionex utilizes an extended-release polistirex formulation, the potential for delayed absorption or a relapse of severe respiratory depression must be considered. Consequently, continuous observation and supportive treatment are mandated regulatory requirements following initial intervention, particularly in older adults who may exhibit greater sensitivity to the drug’s effects.

Therapeutic Uses of Tussionex

The core therapeutic purpose of Tussionex is to provide supportive relief for cough and upper respiratory symptoms. It is commonly used to help with acute or disruptive episodes associated with conditions like the common cold and seasonal allergies.

The medication is applied in situations involving certain distressing symptoms, primarily a persistent, non-productive cough that has not been adequately controlled by conventional non-narcotic options. The key therapeutic benefit is to provide sustained cough suppression, which contributes to easing the overall symptom load and supports the patient during difficult episodes. Indications commonly managed include cough, runny nose, and sneezing.

Tussionex is commonly used to help with symptom clusters that may become intense or disruptive, and plays a role in managing the concurrent manifestations of upper respiratory conditions. The prolonged action, generally lasting up to 12 hours, supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability, which is considered relevant for managing nighttime cough episodes that interfere with functional stability.

Quick Fact: Relief for Persistent Cough The medication is considered relevant when symptoms present with heightened physiological activity that requires an antitussive and antihistamine combination, offering sustained comfort that assists with maintaining functional stability.

Eligibility and Restrictions for Use

Tussionex is subject to strict eligibility rules set by regulatory authorities, largely due to the risks associated with the opioid component, hydrocodone. The medicine is contraindicated and must not be used in several patient populations. This includes all children younger than 6 years of age due to the risk of fatal respiratory depression. Contraindication also applies to patients with significant respiratory depression, uncontrolled severe asthma, gastrointestinal obstruction (like paralytic ileus), or a known allergy to the active ingredients. Furthermore, use is prohibited in patients taking a Monoamine Oxidase Inhibitor (MAOI) or within 14 days of stopping one.

The regulatory labeling imposes further age-based limitations. It is not indicated for any pediatric patients under 18 years of age. Use is reserved only for adults 18 years and older for whom alternative, non-narcotic treatments have been assessed and found inadequate. Caution is also advised in patients with chronic pulmonary disease or head injury.

Conditional use or specific restriction warnings apply to the following groups:

Population Group	Eligibility Status
Pregnant Women	Avoid Use (Risk of Neonatal Opioid Withdrawal Syndrome)
Breastfeeding Women	Not Recommended
Severe Hepatic/Renal Impairment	Use with Caution
Elderly Patients	Use with Caution

What should I know about interactions with other medicines?

The regulatory profile for Tussionex is structured by officially documented pharmacological and metabolic patterns, detailing specific co-administration restrictions for the combination product.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally classified as contraindicated. A mandatory timing rule requires that use must be separated by at least 14 days following the discontinuation of an MAOI. Consumption of Alcohol (Ethanol) is also prohibited, as it is documented to increase hydrocodone plasma concentrations, raising the risk of overdose.

Pharmacokinetic and Pharmacodynamic Interactions

The most clinically significant interactions are categorized by their effect on drug exposure or combined system effects:

Central Nervous System (CNS) Depressants: Combining with other CNS depressants, including Benzodiazepines, other Opioids, and certain Antihistamines, results in an additive pharmacodynamic effect. This interaction can lead to profound sedation and respiratory depression, and co-administration is labeled to be avoided.
CYP450 Enzyme Modulators: The drug’s metabolism involves Cytochrome P450 enzymes. The official label specifies that co-administration with CYP3A4 Inhibitors (e.g., macrolide antibiotics) may increase the plasma concentration of hydrocodone, while CYP3A4 Inducers (e.g., Rifampin) may decrease it, potentially leading to reduced efficacy or withdrawal.
Anticholinergic and Serotonergic Drugs: Concomitant use with other anticholinergic drugs has the documented risk of producing paralytic ileus. Co-administration with serotonergic medicines (such as SSRIs) carries the official warning for the potential development of serotonin syndrome.

Procedural Constraint

To preserve the drug’s extended-release properties, the suspension must not be diluted or mixed with any other fluids or drugs, as this action compromises the resin technology, which changes the absorption rate and increases toxicity risk.

Mechanism of Action

How Tussionex Works

Hydrocodone, a semi-synthetic opioid agonist, selectively activates mu-Opioid Receptors ( MOR) located within the brainstem's Medullary Cough Center. This molecular engagement initiates a neural cascade that elevates the cough threshold, thereby dampening the transmission of afferent signals and resulting in the systemic physiological consequence of an elevated threshold for reflex initiation.

The second component of the mechanism involves Phenyltoloxamine, a first-generation antihistamine that acts as a competitive antagonist at Histamine H1 Receptors ( H1 R). This H1 R blockade affects the histaminergic pathway, leading to a physiological consequence of CNS depression and sedation, which operates additively with the central suppressive action of Hydrocodone.

The time course of the mechanism is governed by the polistirex resin formulation, which chemically regulates the rate of release for both active agents. This unique delivery mechanism ensures consistent receptor engagement for MOR and H1 R targets over approximately 12 hours, resulting in a sustained duration of MOR and H1 R engagement.

Dosage and Administration Information

How to Use Tussionex: Administration Guidelines

Tussionex extended-release oral suspension (hydrocodone polistirex and chlorpheniramine polistirex) is administered according to a protocol. The extended-release nature of the medication necessitates a fixed, infrequent dosing schedule to ensure consistent availability of the active ingredients.

Administration Protocol

The medicine is for oral use only and is provided as a liquid suspension. It may be taken with or without food.

Prior to measuring, the suspension must be shaken well. To ensure accurate delivery of the intended dose, the liquid must be measured using an accurate milliliter measuring device; the use of a common household spoon is not acceptable. The suspension must not be diluted with fluids or mixed with other drugs.

Population	Single Dose Volume	Maximum Doses per 24 Hours
Adults and Children ge 12 years	5 mL	2 Doses (10 mL total)
Children 6–11 years	2.5 mL	2 Doses (5 mL total)

Frequency and Duration of Use

Standard dosing is for a fixed interval of every 12 hours (q12hr), limiting total daily intake to a maximum of two doses. The medicine should be used for the shortest duration consistent with treatment goals. If the cough does not respond, the patient's condition should be reevaluated within 5 days or sooner.

Population-Specific Use

Use is contraindicated in children less than six years of age. For older adults, dose selection should be cautious, generally starting at the low end of the dosing range, a practice that reflects the greater incidence of decreased organ function in this population.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tussionex

H2: Evidence for Use in Acute Cough and Upper Respiratory Symptoms

The research base for Tussionex, a combination of an antitussive and an antihistamine, includes studies that explored outcomes related to physical discomfort in adults experiencing conditions associated with acute or disruptive episodes of cough. The evidence primarily consists of foundational Randomized Controlled Trials (RCTs), often conducted in a double-blind manner, which research examined patterns related to the active ingredients and the cough reflex.

These studies reported on symptom measurements in the observed populations, primarily focusing on patient-reported outcomes describing perceived discomfort and the measured intensity of the cough. The findings describe patterns observed in the studies that contribute to the broader evidence landscape related to cough symptom patterns. However, the available data for the opioid antitussive drug class, in general, was associated with limited and mixed findings when managing acute cough related to common upper respiratory tract infections.

H2: Research Exploring the Extended-Release Formulation

Specific research examined the performance of the liquid suspension's extended-release technology. These comparative studies explored the duration of effect by monitoring the active ingredients in the body over defined time intervals. This research explored how the sustained-release formula was observed in comparison to immediate-release liquids.

The studies data show patterns related to the prolonged presence of the active components, and research describes the measured duration of action compared to short-acting liquids. This research contributes to understanding the patterns of symptom change observed when the formulation is used in research exploring short-term symptom changes.

H2: Long-Term Follow-up and Durability of Observed Patterns

The evidence primarily addresses short-term, acute symptom patterns. However, research has explored the characteristics of long-term outcomes related to the active components. Older literature includes observational data and case reports where the medication was observed in certain populations to manage conditions characterized by fluctuating or episodic manifestations of cough over extended periods.

These limited, non-randomized studies findings describe patterns observed in the studies over follow-up periods that may have spanned up to 29 months. While this research contributes to the broader evidence landscape, the findings provide limited insight into the long-term patterns when the medication is used continuously for extended periods.

H2: Evidence in Specific Patient Populations

Research has explored the effects of Tussionex was evaluated in different age groups, primarily focusing on Adults (ge 18 years). Scientific reviews have also addressed the evidence base for geriatric patients (adults over 65). The research describes specific patterns in this group, which is relevant in studies involving physiological strain or stress.

A critical limitation in the research is the evidence for children. Systematic reviews commissioned by regulatory bodies noted that data for certain groups remain insufficient, specifically reporting a significant lack of robust, controlled clinical data demonstrating effectiveness in the pediatric population (under 18 years old). This finding from the research base was associated with changes in regulatory guidelines regarding the populations studied for this product.

H2: Evidence Gaps and Areas of Uncertainty

The existing research base has several known limitations. The core efficacy data for the combination was observed in some studies that were conducted in prior decades, meaning the evidence quality varies across studies compared to modern trial standards.

Furthermore, follow-up durations were limited in many of the key studies supporting acute use. The main outcomes focus on subjective endpoints, such as patient-reported cough frequency, and comparative evidence is lacking for objective, biological measures. Therefore, long-term effects are not fully established, and certainty remains low regarding some aspects of the research.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Tussionex (FAQ)

Q: How quickly is Tussionex supposed to start working?

A: Official information indicates that Tussionex is an extended-release oral suspension formulated for a sustained effect, with a typical dosing interval of every 12 hours. While the formulation is designed for prolonged relief, official product information does not specify a precise timeframe for the initial onset of the cough-suppressing action.

Q: How long does the effect of Tussionex typically last?

A: Tussionex is an extended-release medication. According to official regulatory documents, the dosing schedule is set for every 12 hours to ensure the active ingredients remain effective over that period and provide sustained relief.

Q: Can I drive or operate machinery while taking Tussionex?

A: Official labeling notes caution, as the drug may cause effects like drowsiness, sedation, or dizziness. These effects can lead to impaired mental and/or physical abilities. Regulatory documents state that this impairment may affect a person's ability to perform hazardous tasks.

Q: What is the risk of overdose with Tussionex?

A: Official regulatory information includes a Boxed Warning that highlights the risk of overdose, which can be fatal. The risk is increased if the drug is accidentally ingested by a child or if it is used concurrently with other central nervous system depressants, such as alcohol.

Q: Can older adults use Tussionex safely?

A: Official documentation notes that use in the elderly requires caution. Older adults may be more susceptible to adverse effects, including the risk of respiratory depression (slowed or shallow breathing). The official guidance reflects greater cautiousness regarding dose selection in this population.

Q: How often do people usually need to take Tussionex?

A: The official dosage schedule for the extended-release suspension is every 12 hours as needed. The official schedule strictly limits the total intake to a maximum of two doses in a 24-hour period.

Q: Does Tussionex show up on standard drug tests?

A: Tussionex contains hydrocodone, which is classified as an opioid. Regulatory sources state that hydrocodone is an ingredient that may be detected in standard drug screenings.

Q: Is Tussionex used to treat just a cough, or does it also help with colds?

A: The drug is indicated for the temporary relief of cough and upper respiratory symptoms. Regulatory documents specifically include symptoms associated with the common cold or allergy as indications for use.

Q: Why is Tussionex classified as a controlled substance?

A: Tussionex is officially classified by the DEA as a Schedule CII controlled substance. This classification is due to the presence of hydrocodone, an opioid component that has a known potential for abuse and misuse.

Q: What happens if I miss a dose of Tussionex?

A: Official guidance describes that a missed dose is generally taken as soon as it is remembered. However, if it is almost time for the next dose, the missed dose is generally skipped entirely. The patient information emphasizes returning to the regular schedule and notes that taking double or extra doses is avoided.

Q: Is Tussionex linked to withdrawal symptoms if stopped suddenly?

A: Official labeling notes that physical dependence may occur with prolonged use of the opioid component. If physical dependence has developed, suddenly discontinuing the medication may lead to unwanted withdrawal effects.

Q: Is there a generic version of Tussionex available?

A: Tussionex is the brand name for the combination of hydrocodone polistirex and chlorpheniramine polistirex. Regulatory bodies list approved drug products, and generic versions containing these same active ingredients in the extended-release formulation may be available.

Q: Are there different strengths of Tussionex available?

A: Official drug information confirms that the extended-release oral suspension is available in one concentration. This single strength contains hydrocodone equivalent to 10 mg and chlorpheniramine equivalent to 8 mg per 5 mL.

Q: Does Tussionex contain acetaminophen (Tylenol)?

A: Official documentation lists the active ingredients as hydrocodone polistirex and chlorpheniramine polistirex. Acetaminophen (Tylenol) is not listed as an active ingredient in this formulation.

Q: Is Tussionex a treatment for bronchitis?

A: The drug is officially indicated for temporary relief of cough and upper respiratory symptoms associated with allergy or the common cold. Bronchitis is not specifically listed as one of the indications in the regulatory documentation.

Q: Is the antihistamine in Tussionex for allergy relief?

A: Yes, Tussionex is indicated for symptoms associated with allergy or the common cold. The antihistamine component, chlorpheniramine, is a drug class used to address these allergy-related symptoms.

Q: Why is the drug sometimes described as a combination medicine?

A: The medication is officially described as a combination product because it contains two distinct active ingredients. It combines an opioid antitussive (hydrocodone) and a histamine-1 receptor antagonist (chlorpheniramine) to address multiple symptoms.

Q: Does Tussionex interact with over-the-counter pain relievers like ibuprofen?

A: Official regulatory warnings focus on interactions with specific classes of drugs, such as CNS depressants, MAOIs, and certain antidepressants. Over-the-counter pain relievers such as ibuprofen are not explicitly listed in the core interaction warnings in the official product labeling.

Q: Is Tussionex approved for pain relief as well as cough?

A: Regulatory documents state that the drug is indicated only for the temporary relief of cough and associated upper respiratory symptoms. It is not indicated for use as a pain reliever.

Q: What is the difference between Tussionex and hydrocodone/chlorpheniramine products?

A: Tussionex is a brand name for the extended-release liquid containing the specific active ingredients hydrocodone polistirex and chlorpheniramine polistirex. The brand name is simply the identity of that specific combination product.

Q: What is the standard duration of treatment with Tussionex?

A: Official guidance states that the drug should be prescribed for the shortest duration consistent with treatment goals. Official guidance describes that if the cough does not improve, reevaluation of the patient's condition within 5 days or sooner is indicated.

Q: Why does the packaging for Tussionex list several warnings?

A: Official packaging includes a Boxed Warning to notify users about the most serious risks. These risks include the potential for addiction, abuse, and misuse, and the possibility of life-threatening respiratory depression (slowed or shallow breathing).

Q: Is Tussionex associated with any issues for people with glaucoma?

A: Official documentation advises that the drug should be used with caution in patients who have narrow-angle glaucoma.

How should Tussionex be stored and disposed of?

How to Store and Dispose of Tussionex

Storage and disposal of Tussionex Extended-Release Oral Suspension are governed by specific regulatory requirements to ensure product stability and prevent harm from accidental exposure.

Storage Conditions

Tussionex must be stored at Controlled Room Temperature, defined as 68 F to 77 F (20 C to 25 C). The suspension must not be frozen or exposed to excessive heat. It must be kept in a tightly closed container and must not be diluted or mixed with other liquids, as this compromises the extended-release formulation.

Child Safety and Disposal

Due to the presence of hydrocodone, Tussionex must be stored out of the sight and reach of children in a safe, secure location. For disposal of unused or expired medicine, the official procedure requires returning it to a drug take-back location or, if unavailable, flushing it down the toilet as per specific government guidance for certain dangerous opioids.

Tussionex